NCT01503229View on ClinicalTrials.gov

Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

March 12, 2020

Study Completion Date

March 12, 2020

Conditions
Hormone-Resistant Prostate CancerMetastatic Prostate CarcinomaRecurrent Prostate CarcinomaStage IV Prostate Adenocarcinoma
Interventions
DRUG

Abiraterone Acetate

Given by mouth

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Prednisone

Given PO

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT01503229 - Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter